Dr. Orndorff is a seasoned business executive, scientist and serial entrepreneur with 30 years experience in the biotechnology industry in various roles of management, business development, R&D, commercialization and manufacturing. Prior to joining Renew, Dr. Orndorff was Chief Operating Officer of Teewinot Life Sciences, a leader in the biocatalytic production of rare cannabinoids, and President and CEO of the drug discovery affiliate company, Canalis Pharmaceuticals. He was President and CEO of IM Therapeutics, a clinical stage drug development company developing small molecule immunotherapeutic precision medicine drugs for Type 1 diabetes and Celiac disease. Also, Dr. Orndorff was President and CEO of Microbiome Therapeutics, a clinical stage company with microbiome modulators for Type 2 diabetes and obesity, and previously was founder and CEO of Accera, a clinical drug development company with a pharmacogenomic-based therapeutic for Alzheimer’s disease. He is past chairman of the Colorado Institute for Drug, Device and Diagnostic Development, the Colorado BioScience Association, and former president of the Society for Industrial Microbiology. Dr. Orndorff holds a B.S. in biology from Virginia Tech and a Ph.D. in microbiology from the University of Maryland.
Joseph P. Noel, Ph.D. SCIENCE ADVISOR & CO-FOUNDER
Dr. Noel is a Professor and Director of the Jack H. Skirball Center for Chemical Biology and Proteomics at The Salk Institute for Biological Studies and an Investigator with the Howard Hughes Medical Institute. He holds the Arthur and Julie Woodrow Chair at the Salk Institute. Dr. Noel’s research seeks to decipher the core principles influencing evolutionary change in proteins and protein networks, particularly enzymes and metabolic pathways underlying the emergence and rapid expansion of chemical diversity in living systems. The ultimate goal of the work is to understand the chemical, structural and evolutionary tenets governing this extraordinary form of biodiversity and biocomplexity. Dr. Noel focuses on the intricate biosynthetic pathways plants and microbes use to produce the vast array of compounds that allow them to survive and prosper in the multitude of challenging ecosystems found all over the earth. Some of these natural chemicals are used for “communication” with other species in the their local environment and some are used for their own defense – both as natural chemical weapons against other organisms or as chemical strategies to adapt to challenging physical environments. Such compounds are also a rich source of new drugs. In addition to understanding the chemistry and evolutionary principles that underlie this extraordinary biological diversity, Dr. Noel also seeks to harness and alter these pathways to produce chemical “scaffolds” that can provide the starting point for the development of new drugs. Dr. Noel’s research has concentrated on the biosynthetic machinery for three important classes of natural compounds, polyketides, terpenes and terpene-polyketide hybrids. These chemicals have played an important role in the pharmaceutical industry as sources of new drugs. By understanding the detailed structures and functions of the enzymes that produce these compounds, how these enzyme structures have evolved over time, and how these enzymes organize themselves in space and time in cells forming complex metabolic pathways, Noel advances plant metabolic engineering by creating new versions of the biosynthetic enzymes and pathways that can synthesize altered compounds as a potential source of new biological tools and future pharmaceuticals. Joe received a B.S. in natural sciences/chemistry from the University of Pittsburgh at Johnstown and a Ph.D. in chemistry from The Ohio State University and postdoctoral studies at Yale University in structural biology with the late Paul B. Sigler.
Dr. Deaver brings extensive expertise and experience to Renew in medicinal chemistry, non-clinical pharmacology, toxicology and the drug discovery, development and approval processes.
Dr. Deaver spent 17 years at Alkermes, Inc., where he directed life sciences and toxicology before becoming vice president of non-clinical research and development. Prior to that, he spent several years as a professor and graduate program chair at Penn State University.
Dr. Deaver spent many years developing strategies for toxicology programs to support all states of clinical development, from Phase 1 through NDA submission. He has provided scientific leadership in designing and executing toxicology programs to support a variety of drug candidates including inhaled proteins, inhaled small molecules, injectable extended release drug products, orally delivered small molecules and a biologic for oncology.
He has established expertise in both cell-based and mouse models, with a focus on GPCR ligands and receptors.
He has been awarded numerous U.S. patents, and has been published extensively in various professional and academic journals, and book chapters.
Dr. Deaver received his bachelor’s and master’s degrees from University of Maryland College Park, and his PhD degree from West Virginia University, Morgantown.
Nick is a world-renowned expert in neurosurgery and clinical neuroscience. He is a co-founder of Coda Biotherapeutics focused on developing novel viral vector technology to treat neuropathic pain, epilepsy, movement disorders and other severe nervous system disorders.
Dr. Boulis is also a practicing neurosurgeon and a professor of neurosurgery at Emory University where his lab focuses on the development of gene and cellular therapies for neurodegenerative and functional diseases of the nervous system. A variety of viral vectors are currently being tested in both neuronal cell cultures and in animal models of ALS and spinal muscular atrophy. In parallel, the Boulis laboratory focuses on the development of tissue-specific targeting strategies. These approaches are designed to deliver molecular therapeutics to an anatomically defined site of interest. Much of this effort has concentrated on motor neuron-specific gene delivery. In 2004, Dr. Boulis began to concentrate on the development of surgical techniques for spinal cord cell transplantation. In the context of this work, he developed techniques and devices allowing for accurate human spinal cord transplantation and has provided support for a variety of teams interested in spinal cord transplantation in the United States and Europe. Dr. Boulis is the author or co-author of dozens of internationally published and peer-reviewed articles, journals and book chapters.
Dr. Ken Mackie is a Professor of Psychological and Brain Sciences at Indiana University, Bloomington, IN (IUB) and an Adjunct Professor of Anesthesiology at Indiana University School of Medicine. He is also the Linda and Jack Gill Chair of Neuroscience and the Director of the Gill Center for Biomolecular Science at IUB.
Professor Mackie’s research is focused on cannabinoid receptors, the cell surface receptors responsible for most of the psychoactive and therapeutic actions. His team at the Gill Center for Biomolecular Science uses a variety of techniques, including electrophysiological, molecular, immunological, and imaging, to better understand how cannabinoid receptors signal and how their signaling interacts with other cellular processes. Much of the current work in his lab centers on endogenous cannabinoids (endocannabinoids), compounds produced by the body that interact with cannabinoid receptors. These molecules have been implicated in processes as diverse as memory, analgesia, anxiety, schizophrenia, and obesity. One of the recent results from his group suggests that cannabis produces some of its effects by blocking the normal actions of endocannabinoids. This contrasts with the mode of action of opiates, which appear to produce their psychoactivity by mimicking the effects of endogenous opiates (endorphins).
Dr. Mackie received his MD from Yale University, and completed his Internal Medicine Internship in the Yale system and Anesthesiology Residency at the University of Washington. He did post-doctoral work at Rockefeller University and the University of Washington. For fifteen years he combined an active laboratory research program in cannabinoid research with clinical care in anesthesiology at the University of Washington. In 2007 he was recruited to IUB as a Gill Chair in neuroscience. Dr. Mackie’s research interests focus on understanding the relationships between cannabinoids (such as THC and CBD), endocannabinoids, and the pharmacological and physiological responses to both. His lab takes diverse approaches (imaging, electrophysiological, behavioral, molecular, and biochemical) to address these questions. He has served on numerous national and international review boards and has taken an active role in organizing cannabinoid-themed meetings. Dr. Mackie is a member of several professional societies including the Society for Neuroscience, the American Society for Pharmacology and Experimental Therapeutics, the International Cannabinoid Research Society, and the American Society of Anesthesiologists.
Morgan, D.J., B.J. Davis, C.S. Kearn, D. Marcus, A.J. Cook, J. Wager-Miller, A. Straiker, M.H. Myoga, J. Karduck, E. Leishman, L.J. Sim-Selley, T.A. Czyzyk, H.B. Bradshaw, D.E. Selley, and K. Mackie, Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice. J Neurosci, 2014. 34(15): p. 5152-63.
Ramikie, T.S., R. Nyilas, R.J. Bluett, J.C. Gamble-George, N.D. Hartley, K. Mackie, M. Watanabe, I. Katona, and S. Patel, Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron, 2014. 81(5): p. 1111-25.
O’Donnell, B.F. and K. Mackie, The mismatch negativity: a translational probe of auditory processing in cannabis users. Biol Psychiatry, 2014. 75(6): p. 428-9.
Petrov, R.R., L. Knight, S.R. Chen, J. Wager-Miller, S.W. McDaniel, F. Diaz, F. Barth, H.L. Pan, K. Mackie, C.N. Cavasotto, and P. Diaz, Mastering tricyclic ring systems for desirable functional cannabinoid activity. Eur J Med Chem, 2013. 69: p. 881-907.
Chen, D.H., A. Naydenov, J.L. Blankman, H.C. Mefford, M. Davis, Y. Sul, A.S. Barloon, E. Bonkowski, J. Wolff, M. Matsushita, C. Smith, B.F. Cravatt, K. Mackie, W.H. Raskind, N. Stella, and T.D. Bird, Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects. Hum Mutat, 2013. 34(12): p. 1672-8.
Jain, T., J. Wager-Miller, K. Mackie, and A. Straiker, Diacylglycerol lipasealpha (DAGLalpha) and DAGLbeta cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons. Mol Pharmacol, 2013. 84(2): p. 296-302.
Cristino, L., G. Busetto, R. Imperatore, I. Ferrandino, L. Palomba, C. Silvestri, S. Petrosino, P. Orlando, M. Bentivoglio, K. Mackie, and V. Di Marzo, Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc Natl Acad Sci U S A, 2013. 110(24): p. E2229-38.
Straiker, A., K.T. Min, and K. Mackie, Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. Neurobiol Dis, 2013. 56: p. 1-5.
Shonesy, B.C., X. Wang, K.L. Rose, T.S. Ramikie, V.S. Cavener, T. Rentz, A.J. Baucum, 2nd, N. Jalan-Sakrikar, K. Mackie, D.G. Winder, S. Patel, and R.J. Colbran, CaMKII regulates diacylglycerol lipase-alpha and striatal endocannabinoid signaling. Nat Neurosci, 2013. 16(4): p. 456-63.
Keimpema, E., G. Tortoriello, A. Alpar, S. Capsoni, I. Arisi, D. Calvigioni, S.S. Hu, A. Cattaneo, P. Doherty, K. Mackie, and T. Harkany, Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. Proc Natl Acad Sci U S A, 2013. 110(5): p. 1935-40.
Atwood, B.K., A. Straiker, and K. Mackie, CB(2) cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology, 2012. 63(4): p. 514-23.
Atwood, B.K., A. Straiker, and K. Mackie, CB(2): therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry, 2012. 38(1): p. 16-20.
Atwood, B.K., J. Wager-Miller, C. Haskins, A. Straiker, and K. Mackie, Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol, 2012. 81(2): p. 250-63.
Straiker, A., J. Wager-Miller, J. Hutchens, and K. Mackie, Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br J Pharmacol, 2012. 165(8): p. 2660-71.
Straiker, A., J. Wager-Miller, and K. Mackie, The CB1 cannabinoid receptor C-terminus regulates receptor desensitization in autaptic hippocampal neurones. Br J Pharmacol, 2012. 165(8): p. 2652-9.
Ho, Y.C., H.J. Lee, L.W. Tung, Y.Y. Liao, S.Y. Fu, S.F. Teng, H.T. Liao, K. Mackie, and L.C. Chiou, Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J Neurosci, 2011. 31(41): p. 14600-10.
Straiker, A., J. Wager-Miller, S.S. Hu, J.L. Blankman, B.F. Cravatt, and K. Mackie, COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation. Br J Pharmacol, 2011. 164(6): p. 1672-83.
Atwood, B.K., D. Lee, A. Straiker, T.S. Widlanski, and K. Mackie, CP47,497-C8 and JWH073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol, 2011. 659(2-3): p. 139-45.
Wu, C.S., J. Zhu, J. Wager-Miller, S. Wang, D. O’Leary, K. Monory, B. Lutz, K. Mackie, and H.C. Lu, Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci, 2010. 32(5): p. 693-706.
Marrs, W.R., J.L. Blankman, E.A. Horne, A. Thomazeau, Y.H. Lin, J. Coy, A.L. Bodor, G.G. Muccioli, S.S. Hu, G. Woodruff, S. Fung, M. Lafourcade, J.P. Alexander, J.Z. Long, W. Li, C. Xu, T. Moller, K. Mackie, O.J. Manzoni, B.F. Cravatt, and N. Stella, The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci, 2010. 13(8): p. 951-7.
Atwood, B.K. and K. Mackie, CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol, 2010. 160(3): p. 467-79.
Atwood, B.K., J. Huffman, A. Straiker, and K. Mackie, JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol, 2010. 160(3): p. 585-93.
Straiker, A., S.S. Hu, J.Z. Long, A. Arnold, J. Wager-Miller, B.F. Cravatt, and K. Mackie, Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol, 2009. 76(6): p. 1220-7.
Straiker, A. and K. Mackie, Cannabinoid signaling in inhibitory autaptic hippocampal neurons. Neuroscience, 2009. 163(1): p. 190-201.
Kellogg, R., K. Mackie, and A. Straiker, Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons. J Neurophysiol, 2009. 102(2): p. 1160-71.
Daigle, T.L., M.L. Kwok, and K. Mackie, Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem, 2008. 106(1): p. 70-82.
Dr. Burkart is a Professor of Chemistry and Biochemistry at the University of California, San Diego and Associate Director of the California Center for Algae Biotechnology. An internationally recognized expert in natural product biosynthesis and metabolic pathway engineering, his research interests include natural product synthesis and biosynthesis, enzyme mechanism, and metabolic engineering. Prof. Burkart has been a fellow of the Alfred P. Sloan Foundation and Ellison Medical Foundation, was the RSC Organic and Biomolecular Chemistry Lecturer for 2010, and was elected Fellow of the Royal Society of Chemistry in 2016. He received a BA in chemistry from Rice University in 1994. He received a PhD in Organic Chemistry from the Scripps Research Institute in 1999, after which time he pursued postdoctoral studies at Harvard Medical School.
Renew’s portfolio includes both new and licensed intellectual property and technological capabilities.
This portfolio enables Renew to engineer enzymes to create a prolific pipeline of proprietary derivative molecules for pharmaceutical drug development.
FOR MORE INFORMATION ON RENEW’S PATENTS CLICK HERE: